MediciNova, Inc. (NASDAQ:MNOV - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $8.3333.

Several brokerages have weighed in on MNOV. D. Boral Capital reissued a "buy" rating and set a $9.00 price target on shares of MediciNova in a research report on Monday, May 4th. Weiss Ratings restated a "sell (d-)" rating on shares of MediciNova in a research report on Wednesday, June 24th.

Read Our Latest Stock Report on MNOV

MediciNova Price Performance

Shares of MNOV stock opened at $1.32 on Friday. The business has a 50-day moving average of $1.35 and a 200 day moving average of $1.44. MediciNova has a 1-year low of $1.17 and a 1-year high of $1.96. The stock has a market capitalization of $64.97 million, a PE ratio of -5.74 and a beta of 0.62.

MediciNova (NASDAQ:MNOV - Get Free Report) last announced its quarterly earnings data on Thursday, May 14th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.01. MediciNova had a negative return on equity of 27.28% and a negative net margin of 1,962.98%.The firm had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.19 million. Analysts anticipate that MediciNova will post -0.26 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. State Street Corp raised its position in MediciNova by 10.9% during the 4th quarter. State Street Corp now owns 193,698 shares of the biopharmaceutical company's stock valued at $254,000 after purchasing an additional 19,100 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of MediciNova in the 4th quarter worth approximately $214,000. Citadel Advisors LLC bought a new stake in shares of MediciNova in the 3rd quarter worth approximately $92,000. Goldman Sachs Group Inc. purchased a new position in shares of MediciNova during the fourth quarter valued at approximately $35,000. Finally, StoneX Group Inc. purchased a new position in shares of MediciNova during the fourth quarter valued at approximately $25,000. Hedge funds and other institutional investors own 9.90% of the company's stock.

MediciNova Company Profile

(Get Free Report)

MediciNova, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule therapeutics for neurodegenerative, inflammatory, fibrotic and oncological diseases. Founded in the late 1990s, the company advances its proprietary compounds through clinical trials and strategic partnerships, with a goal of addressing areas of high unmet medical need. MediciNova is headquartered in San Diego, California, and maintains a presence in Tokyo to support collaborations and regulatory interactions in Asian markets.

The company's leading clinical asset, MN-166 (ibudilast), is an anti-inflammatory and neuroprotective agent originally approved in Japan for asthma and post-stroke dizziness.

Recommended Stories

• Five stocks we like better than MediciNova
• Telecom Earnings Reveal a Sector That Finally Looks Healthier
• Defense Earnings Show Readiness Now and Modernization Ahead
• Why Palantir Investors Aren't Panicking While the Rest of AI Sells Off
• MarketBeat Week in Review – 07/20- 07/24

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in MediciNova Right Now?

Before you consider MediciNova, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediciNova wasn't on the list.

While MediciNova currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here